Biofrontera

Biofrontera Net Change in Cash

The Net Change in Cash of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 479,000.00 EUR. In the previous year, Net Change in Cash was 44,000.00 EUR — a change of 988.64% (higher).

Net Change in Cash

479,000.00EUR

YoY

988.64%

Last updated:

Net Change in Cash of Biofrontera is 2025 479,000.00 EUR. Net Change in Cash of Biofrontera was 2024 44,000.00 EUR. It decreases by 988.64% higher compared to the previous year.

The Biofrontera Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
8.37 M EUR
Jan 1, 2019
-8.33 M EUR
Jan 1, 2020
5.43 M EUR
Jan 1, 2021
-9.64 M EUR
Jan 1, 2022
-532,000.00 EUR
Jan 1, 2023
-3.30 M EUR
Jan 1, 2024
44,000.00 EUR
Jan 1, 2025
479,000.00 EUR
The Biofrontera Net Change in Cash history
YEARNet Change in CashYoY
479,000.00EUR+988.64%
44,000.00EUR-101.33%
-3.30 MEUR+519.55%
-532,000.00EUR-94.48%
-9.64 MEUR-277.59%
5.43 MEUR-165.13%
-8.33 MEUR-199.57%
8.37 MEUR-306.98%
-4.04 MEUR-136.21%
11.17 MEUR-345.42%
-4.55 MEUR-181.61%
5.58 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Net Change in Cash of Biofrontera is 479,000.00 EUR in 2025.

Net Change in Cash of Biofrontera changed from 44,000.00 EUR to 479,000.00 EUR, representing a 988.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biofrontera

All Key Metrics — Biofrontera